BlackRock’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.31B | Buy |
13,711,607
+326,000
| +2% | +$48.4M | 0.03% | 408 |
|
|
2026
Q1 | $1.76B | Buy |
13,385,607
+555,010
| +4% | +$73.6M | 0.03% | 452 |
|
|
2025
Q4 | $1.82B | Buy |
12,830,597
+124,367
| +1% | +$18M | 0.03% | 440 |
|
|
2025
Q3 | $1.78B | Sell |
12,706,230
-248,535
| -2% | -$33.7M | 0.03% | 441 |
|
|
2025
Q2 | $1.63B | Sell |
12,954,765
-1,727,629
| -12% | -$198M | 0.03% | 454 |
|
|
2025
Q1 | $1.62B | Sell |
14,682,394
-100,328
| -0.7% | -$12.7M | 0.03% | 446 |
|
|
2024
Q4 | $2.02B | Buy |
14,782,722
+526,674
| +4% | +$65.1M | 0.04% | 384 |
|
|
2024
Q3 | $1.64B | Buy |
14,256,048
+65,340
| +0.5% | +$8.96M | 0.03% | 447 |
|
|
2024
Q2 | $1.95B | Buy |
14,190,708
+429,738
| +3% | +$58.9M | 0.04% | 367 |
|
|
2024
Q1 | $1.9B | Buy |
13,760,970
+113,079
| +0.8% | +$15.4M | 0.04% | 380 |
|
|
2023
Q4 | $1.8B | Buy |
13,647,891
+276,493
| +2% | +$31.8M | 0.05% | 369 |
|
|
2023
Q3 | $1.5B | Sell |
13,371,398
-110,744
| -0.8% | -$11.7M | 0.04% | 397 |
|
|
2023
Q2 | $1.27B | Buy |
13,482,142
+15,492
| +0.1% | +$1.51M | 0.04% | 463 |
|
|
2023
Q1 | $1.36B | Buy |
13,466,650
+838,997
| +7% | +$87.3M | 0.04% | 420 |
|
|
2022
Q4 | $1.51B | Buy |
12,627,653
+580,508
| +5% | +$68M | 0.05% | 379 |
|
|
2022
Q3 | $1.28B | Buy |
12,047,145
+127,555
| +1% | +$12.9M | 0.04% | 411 |
|
|
2022
Q2 | $1.16B | Buy |
11,919,590
+324,173
| +3% | +$29.9M | 0.04% | 458 |
|
|
2022
Q1 | $1.09B | Buy |
11,595,417
+118,872
| +1% | +$10.1M | 0.03% | 551 |
|
|
2021
Q4 | $977M | Buy |
11,476,545
+1,258,312
| +12% | +$116M | 0.02% | 616 |
|
|
2021
Q3 | $980M | Buy |
10,218,233
+79,736
| +0.8% | +$7.53M | 0.03% | 595 |
|
|
2021
Q2 | $987M | Sell |
10,138,497
-850,977
| -8% | -$81.6M | 0.03% | 605 |
|
|
2021
Q1 | $1.07B | Buy |
10,989,474
+3,991,679
| +57% | +$419M | 0.03% | 555 |
|
|
2020
Q4 | $671M | Buy |
6,997,795
+182,933
| +3% | +$17.7M | 0.02% | 705 |
|
|
2020
Q3 | $655M | Sell |
6,814,862
-691,828
| -9% | -$80M | 0.02% | 611 |
|
|
2020
Q2 | $916M | Buy |
7,506,690
+551,286
| +8% | +$60.9M | 0.04% | 460 |
|
|
2020
Q1 | $602M | Buy |
6,955,404
+363,852
| +6% | +$35.6M | 0.03% | 536 |
|
|
2019
Q4 | $709M | Buy |
6,591,552
+655,434
| +11% | +$68.6M | 0.03% | 613 |
|
|
2019
Q3 | $535M | Buy |
5,936,118
+277,587
| +5% | +$25.9M | 0.02% | 701 |
|
|
2019
Q2 | $478M | Buy |
5,658,531
+163,195
| +3% | +$13.4M | 0.02% | 770 |
|
|
2019
Q1 | $484M | Buy |
5,495,336
+516,419
| +10% | +$43.2M | 0.02% | 757 |
|
|
2018
Q4 | $356M | Sell |
4,978,917
-120,359
| -2% | -$11.5M | 0.02% | 870 |
|
|
2018
Q3 | $627M | Buy |
5,099,276
+16,724
| +0.3% | +$1.9M | 0.03% | 629 |
|
|
2018
Q2 | $499M | Buy |
5,082,552
+174,057
| +4% | +$15.6M | 0.02% | 732 |
|
|
2018
Q1 | $407M | Buy |
4,908,495
+132,749
| +3% | +$11.2M | 0.02% | 830 |
|
|
2017
Q4 | $371M | Sell |
4,775,746
-81,372
| -2% | -$5.55M | 0.02% | 908 |
|
|
2017
Q3 | $298M | Buy |
4,857,118
+54,891
| +1% | +$2.9M | 0.02% | 1036 |
|
|
2017
Q2 | $221M | Sell |
4,802,227
-229,706
| -5% | -$11.1M | 0.01% | 1213 |
|
|
2017
Q1 | $218M | Buy |
5,031,933
+4,996,784
| +14,216% | +$214M | 0.01% | 1211 |
|
|
2016
Q4 | $1.36M | Sell |
35,149
-41,659
| -54% | -$1.89M | ﹤0.01% | 1382 |
|
|
2016
Q3 | $3.89M | Buy |
76,808
+4,569
| +6% | +$228K | 0.01% | 978 |
|
|
2016
Q2 | $3.28M | Buy |
72,239
+8,247
| +13% | +$380K | ﹤0.01% | 982 |
|
|
2016
Q1 | $2.53M | Sell |
63,992
-9,408
| -13% | -$373K | ﹤0.01% | 1041 |
|
|
2015
Q4 | $4.15M | Buy |
73,400
+26,591
| +57% | +$1.35M | 0.01% | 889 |
|
|
2015
Q3 | $1.86M | Sell |
46,809
-7,337
| -14% | -$355K | ﹤0.01% | 1077 |
|
|
2015
Q2 | $2.59M | Sell |
54,146
-1,581
| -3% | -$67K | ﹤0.01% | 1035 |
|
|
2015
Q1 | $2.21M | Sell |
55,727
-18,237
| -25% | -$652K | ﹤0.01% | 1056 |
|
|
2014
Q4 | $1.65M | Sell |
73,964
-38,200
| -34% | -$724K | ﹤0.01% | 1102 |
|
|
2014
Q3 | $1.76M | Sell |
112,164
-8,900
| -7% | -$133K | ﹤0.01% | 1086 |
|
|
2014
Q2 | $1.8M | Buy |
121,064
+3,865
| +3% | +$54.5K | ﹤0.01% | 1065 |
|
|
2014
Q1 | $1.89M | Buy |
117,199
+115,012
| +5,259% | +$1.97M | ﹤0.01% | 1067 |
|
|
2013
Q4 | $21K | Hold |
2,187
| – | – | ﹤0.01% | 2340 |
|
|
2013
Q3 | $25K | Hold |
2,187
| – | – | ﹤0.01% | 2156 |
|
|
2013
Q2 | $29K | Buy |
+2,187
| New | +$26.9K | ﹤0.01% | 2099 |
|
Other funds holding NBIX
VPC
BlackRock's NBIX Position: Q2 2026 in Review
BlackRock increased its Neurocrine Biosciences (NBIX) stake by 2.4% in Q2 2026, buying an estimated $48.4M and bringing the position to 13,711,607 shares worth $2.31B. The position accounts for 0.03% of the portfolio, ranked #408.
BlackRock first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. 774 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- BlackRock held 13,711,607 shares of Neurocrine Biosciences worth $2.31B as of Q2 2026.
- BlackRock bought 326,000 Neurocrine Biosciences shares in Q2 2026, an estimated $48.4M.
- Neurocrine Biosciences made up 0.03% of BlackRock's portfolio in Q2 2026, its #408 holding.
- BlackRock first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
- 774 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.